Evidence map›Paper›PMID 32873933›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2021

DOORS syndrome and a recurrent truncating ATP6V1B2 variant.

Eliane Beauregard-Lacroix, Guillermo Pacheco-Cuellar, Norbert F Ajeawung, Jessica Tardif, Klaus Dieterich, Tabib Dabir, Dina Vind-Kezunovic, Susan M White, Denes Zadori, Claudia Castiglioni and 12 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Response to Gao et al.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
  4. Correspondence on "DOORS syndrome and a recurrent truncating ATP6V1B2 variant" by Beauregard-Lacroix et al.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 15 institutions in 9 countries.

Eliane Beauregard-LacroixMedical Genetics Division, Department of Pediatrics, Sainte-Justine University Hospital Center, Montreal, QC, Canada.
Guillermo Pacheco-CuellarMedical Genetics Division, Department of Pediatrics, Sainte-Justine University Hospital Center, Montreal, QC, Canada.
Norbert F AjeawungCHU Sainte Justine Research Center, Université de Montréal, Montreal, QC, Canada.
Jessica TardifMedical Genetics Division, Department of Pediatrics, Sainte-Justine University Hospital Center, Montreal, QC, Canada.
Klaus DieterichUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences (GIN), Grenoble, France.ORCID http://orcid.org/0000-0002-4362-4062
Tabib DabirDepartment of Genetic Medicine, Belfast City Hospital, Belfast, Northern Ireland, UK.
Dina Vind-KezunovicDepartment of Dermatology, Copenhagen University Hospital Bispebjerg, Copenhagen, NV, Denmark.
Susan M WhiteVictorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne, Australia.
Denes ZadoriDepartment of Neurology, Interdisciplinary Excellence Center, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary.
Claudia CastiglioniDepartment of Pediatric Neurology, Clínica Las Condes, Santiago, Chile.
Lisbeth TranebjærgThe Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Pernille Mathiesen TørringDepartment of Clinical Genetics, Odense University Hospital, Odense, Denmark.
Ed BlairOxford Regional Genetics Service, Oxford University Hospitals, Oxford, UK.
Marzena WisniewskaDepartment of Medical Genetics, Poznañ University of Medical Sciences, Poznañ, Poland.
Maria Vittoria CamurriMedical Genetics Division, Department of Pediatrics, Sainte-Justine University Hospital Center, Montreal, QC, Canada.
Yolande van BeverDepartment of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
Sirinart MolidpereeCHU Sainte Justine Research Center, Université de Montréal, Montreal, QC, Canada.
Juliet TaylorGenetic Health Service New Zealand-Northern Hub, Auckland, New Zealand.
Alexandre Dionne-LaporteDepartment of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
Sanjay M SisodiyaDepartment of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
Raoul C M HennekamDepartment of Pediatrics, Amsterdam University Medical Center, Amsterdam, Netherlands.
Philippe M CampeauMedical Genetics Division, Department of Pediatrics, Sainte-Justine University Hospital Center, Montreal, QC, Canada. p.campeau@umontreal.ca.ORCID http://orcid.org/0000-0001-9713-7107
Centre Hospitalier Universitaire Sainte-Justine · CAAmsterdam University Medical Centers · NLBispebjerg Hospital · DKClínica Las Condes · CLErasmus MC · NLInserm · FRMontreal Neurological Institute and Hospital · CANational Hospital for Neurology and Neurosurgery · GBOdense University Hospital · DKOxford University Hospitals NHS Trust · GBPoznan University of Medical Sciences · PLUniversity of Copenhagen · DKUniversity of Szeged · HUUniversity of Ulster · GBVictorian Clinical Genetics Services · AU

Funding

CIHR
6 · The paper itself

Abstract

purposeBiallelic variants in TBC1D24, which encodes a protein that regulates vesicular transport, are frequently identified in patients with DOORS (deafness, onychodystrophy, osteodystrophy, intellectual disability [previously referred to as mental retardation], and seizures) syndrome. The aim of the study was to identify a genetic cause in families with DOORS syndrome and without a TBC1D24 variant.

methodsExome or Sanger sequencing was performed in individuals with a clinical diagnosis of DOORS syndrome without TBC1D24 variants.

resultsWe identified the same truncating variant in ATP6V1B2 (NM_001693.4:c.1516C>T; p.Arg506*) in nine individuals from eight unrelated families with DOORS syndrome. This variant was already reported in individuals with dominant deafness onychodystrophy (DDOD) syndrome. Deafness was present in all individuals, along with onychodystrophy and abnormal fingers and/or toes. All families but one had developmental delay or intellectual disability and five individuals had epilepsy. We also describe two additional families with DDOD syndrome in whom the same variant was found.

conclusionWe expand the phenotype associated with ATP6V1B2 and propose another causal gene for DOORS syndrome. This finding suggests that DDOD and DOORS syndromes might lie on a spectrum of clinically and molecularly related conditions.

Indexed as

EpilepsyIntellectual DisabilityNails, MalformedVacuolar Proton-Translocating ATPasesExomeGTPase-Activating ProteinsHumansPhenotypeATP6V1B2 protein, humanGTPase-Activating ProteinsTBC1D24 protein, humanVacuolar Proton-Translocating ATPasesATP6V1B2 geneDDOD syndromeDOORS syndromeexome sequencingTBC1D24 gene

Identifiers

PMID32873933
OpenAlexW3082876695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.